From the perspective of RARα-mediated myeloid differentiation, EZH2 has been shown to play a role in a rare subtype of AML, acute promyelocytic leukemia (APL), which is generally curable with ATRA-based differentiation therapy (in contrast to non-APL AML) (de The et al., 2017). Here, RARA is linked to acute myeloid leukemia.